Rebirth of the God-level Xueba

Not only Grace, but also Zeneca and pharmaceutical companies from Japan and Norway are paying attention to the scientific research progress of Huarui Laboratory.

After discovering that the number of candidate compounds in Huarui Laboratory had dropped rapidly, several companies inquired about the situation in unison.

The 8 candidate compounds are considered an important node. If the rapid decline is due to safety and other technical reasons, it means that the compound may not pass the animal experiment, but if it is the opposite, it means that the compound has a lot of room for selection.

Ample choice space means that the cost may be greatly reduced.

Yang Rui made more than 30 kinds of compounds in one go, and the synthetic routes he adopted were naturally strange, and some routes were unimaginable with normal thinking.

Still, most of the more than 30 compounds use some expensive raw material or catalyst.

It's not that expensive raw materials or catalysts can't be used in drugs, the problem is profit.

These companies focus on the catalyst formula of coenzyme q10 for profit, and deferiprone is also for profit.

Moreover, compared with the catalyst formula of coenzyme q10, the grade of deferiprone is much higher.

A new drug is also a few core projects every year for a super large company like Pfizer, but for ordinary medium and large pharmaceutical companies, it often represents a fraction of the company's assets.

In short, if a pharmaceutical company can produce a new drug, it will rank among the world's pharmaceutical companies.

Regardless of the fact that there are tens of thousands or even more pharmaceutical companies in the world. Of these, 99 were generic drug companies.

Generic drug companies are not necessarily weak, but original drug companies must be strong. Whether it is the strength of the strength, the strength of the laboratory, or the strength of the spirit, they are all powerful, because the strength, laboratory and spirit brought by a new drug may be converted into money in the future.

Dozens of new drugs appear every year around the world. Half plus half and half plus half and half and more. All belong to multinational pharmaceutical companies.

The remaining ones belong to small and medium-sized pharmaceutical companies, and there may not be one in a year.

This is a risky business.

However, there are still people who have invested in it one after another.

Zeneca is a multinational pharmaceutical company with annual sales of more than 10 billion U.S. dollars. However, the number of new drugs they can add each year is also very limited, usually around three.

Deferiprone might not be a blockbuster, but who knows

Many drugs have been developed for new indications only after they have been marketed. Then it became an aerial bomb with a sales volume of billions and tens of billions.

Therefore, people who originally stared at the coenzyme q10 catalyst inevitably also stared at deferiprone, which has been very successful in animal experiments.

But Yang Rui did not agree to the visits of Zeneca and other companies, let alone Japanese and Norwegian companies.

He didn't even let Grace know the details of his experiments. Only the briefings came from the tiny cubicle, before the others in the morning report.

So, in the next two days, Yang Rui removed a compound again, and then ended his independent work in the laboratory.

The remaining 7 compounds are not too risky, in fact, all of them may be used as finished drugs of deferiprone. Several of them have appeared as generic drugs, so there is naturally no major safety problem.

Yang Rui only needs to follow the steps and let them finish the animal experiments.

And the closer it is to completion, the more curious companies like Zeneca will be.

At this stage,

They are indeed just curious.

However, this curiosity also makes them itchy.

On the third day after Yang Rui screened out the last seven compounds, Frankie directly led a group of people to Peking University.

The so-called monk can't escape the temple if he can run away. When people find Peking University, Yang Rui really can't escape.

Not only can't you run away, but you can't keep a low profile.

A group of foreigners has arrived at the school, everyone must pay attention.

When Yang Rui received the call and went outside to pick up people, Dean Liu also ran out.

"Oh, so many international friends come to visit our school, why don't you tell me, Yang Rui, what is it for this time?" Dean Liu said something like a complaint, his eyes bright like a monkey.

"For the deferiprone research of Huarui Laboratory." Yang Rui explained in one sentence.

Dean Liu naturally knew about this, and said with an "oh", "It's all for this medicine, isn't it to say that it doesn't make money?"

"It won't make money in the short term, but not necessarily in the long run." Yang Rui went on to say, "It's an original drug, and there are many benefits to having an additional patent for an original drug."

"That's to say, it's a shark that smells fishy again." Dean Liu nodded understandingly.

Yang Rui smiled: "It's not that serious, it's the stage of animal experiments, and they won't make any money even if they take it."

There are tens of millions of drugs that pass animal experiments every year, and only a few of them are valuable.

"Then what are you doing here?" Dean Liu's attitude changed rapidly.

"It still smells fishy, ​​but I haven't seen any meat, so I guess it won't be too aggressive."

Yang Rui turned around and took Dean Liu with him to entertain representatives of foreign companies who came from afar.

The director of the cafeteria also went with him and asked along the way: "Do you want to open a private room? What shall we feed them?"

"Just eat the documents." Yang Rui answered simply and neatly, and when he arrived at the place, he really fed a bunch of documents to a group of people.

Arnold and the others were delighted to look through it quickly, and Grace was the first to grab it, saying, "It's too thin."

"After you go back to the laboratory, I will give you a thicker version." Yang Rui smiled and comforted him. After all, he came to work for nothing, so he should be given some privileges.

Grace seemed quite satisfied, but her expression changed slightly, and she just went to read the information.

Arnold muttered to the side, comparing the completion of all aspects of the animal experiments item by item.

Clinical candidate compounds have some hallmark features, and the more of these features, the more necessary it is to conduct clinical trials.

Zeneca is a multinational company that often conducts mergers and acquisitions, and has its own methods. By scoring these characteristics, he can judge the approximate value of a compound.

Frankie quietly helped Arnold calculate, and said: "It is effective in animal models, has no genotoxicity, and has no acute or chronic toxicity. The basic score of 15 can be obtained."

"The target of action has been clinically verified. The iron chelator is very simple, so it counts as 3 points. There is a competitive advantage, but can it be stronger than deferoxamine?"

"It counts as 2 points, a total of 5 points."

"In this way, there are 20 points. In terms of raw materials and costs, these compounds are different. Let me see, they can basically get five points. 25 points." Arnold took a breath.

Zeneca’s calculation formulas range from simple to complex, but they never use 60 points as the standard. With the oral calculation formula they are using now, it is rare for a high score to reach 30 points. The company will usually approach and try to acquire .

Frankie looked down at the document and said, "The 7 backup compounds should be given at least 10 points."

"Well, their animal experiments haven't been completed yet. I don't want to forget about the backup compound. Who knows how many will pass in the end." Arnold didn't want to give a high score of 35 points.

Franky said indifferently: "Because it is a drug for rare diseases, there is a 7-year drug monopoly period, do you want to add points for this?"

Arnold hesitated for a moment, and said: "Although so, rare diseases mean low sales. If the monopoly is to make up for the lack of sales, it will be 3 points."

Although it was just an estimate in private, he was embarrassed that it was too unfair.

Frankie said, "That's 28 points."

"Hmm..." Arnold looked at the row of uncalculated items below, his teeth aching.